{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:47:49Z","timestamp":1761994069797,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["contemporaryclinicaltrials.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.cct.2016.08.010","type":"journal-article","created":{"date-parts":[[2016,8,15]],"date-time":"2016-08-15T08:06:11Z","timestamp":1471248371000},"page":"265-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Clinician-reported lesion measurements in skin infection trials: Definitions, reliability, and association with patient-reported pain"],"prefix":"10.1016","volume":"50","clinical-trial-number":[{"clinical-trial-number":"nct01170221","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01421511","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01519778","registry":"10.18810\/clinical-trials-gov"}],"author":[{"suffix":"III","given":"John H.","family":"Powers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita F.","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carisa","family":"De Anda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Prokocimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2010","series-title":"Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease","key":"10.1016\/j.cct.2016.08.010_bb0005"},{"key":"10.1016\/j.cct.2016.08.010_bb0010","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jval.2015.08.006","article-title":"Clinical outcome assessments: conceptual foundation-report of the ISPOR clinical outcomes assessment - emerging good practices for outcomes research task force","volume":"18","author":"Walton","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.cct.2016.08.010_bb0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1477-7525-8-89","article-title":"Patient reported outcomes: looking beyond the label claim","volume":"8","author":"Doward","year":"2010","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.cct.2016.08.010_bb0030","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial","volume":"309","author":"Prokocimer","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2016.08.010_bb0035","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","article-title":"Tedizolid for 6days versus linezolid for 10days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial","volume":"14","author":"Moran","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.cct.2016.08.010_bb0040","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1128\/AAC.03688-14","article-title":"Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections","volume":"59","author":"Shorr","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cct.2016.08.010_bb0045","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2016.08.010_bb0050","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","author":"Corey","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2016.08.010_bb0055","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-dose oritavancin versus 7\u201310days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study","volume":"60","author":"Corey","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cct.2016.08.010_bb0060","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1179\/jmt.2009.17.3.163","article-title":"Global rating of change scales: a review of strengths and weaknesses and considerations for design","volume":"17","author":"Kamper","year":"2009","journal-title":"J. Man. Manip. Ther."},{"key":"10.1016\/j.cct.2016.08.010_bb0065","first-page":"126","article-title":"Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: a comparison with self-reported symptoms. Outcomes committee of the AIDS Clinical Trials Group","volume":"21","author":"Justice","year":"1999","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.cct.2016.08.010_bb0070","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00005650-200104000-00010","article-title":"Clinical importance of provider-reported HIV symptoms compared with patient-report","volume":"39","author":"Justice","year":"2001","journal-title":"Med. Care"},{"key":"10.1016\/j.cct.2016.08.010_bb0075","series-title":"Center for Drug Evaluation and Research (CDER).Guidance for Industry: Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment","first-page":"1","author":"US Department of Health and Human Services","year":"2013"},{"key":"10.1016\/j.cct.2016.08.010_bb0080","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/cid\/cis566","volume":"55","author":"Talbot","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cct.2016.08.010_bb0085","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bmj.2.3993.101","article-title":"Prontosil in erysipelas","volume":"2","author":"Snodgrass","year":"1937","journal-title":"Br. Med. J."},{"key":"10.1016\/j.cct.2016.08.010_bb0090","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/bmj.2.4014.1156","article-title":"Sulphanilamide in the treatment of erysipelas","volume":"2","author":"Snodgrass","year":"1937","journal-title":"Br. Med. J."},{"author":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use","key":"10.1016\/j.cct.2016.08.010_bb0095"},{"key":"10.1016\/j.cct.2016.08.010_bb0100","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.pain.2011.07.005","article-title":"Validity of four pain intensity rating scales","volume":"152","author":"Ferreira-Valente","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.cct.2016.08.010_bb0105","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1526-5900(03)00716-8","article-title":"Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain","volume":"4","author":"Jensen","year":"2003","journal-title":"J. Pain"},{"key":"10.1016\/j.cct.2016.08.010_bb0110","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1682\/JRRD.2006.05.0051","article-title":"Determining mild, moderate, and severe pain equivalency across pain-intensity tools in nursing home residents","volume":"44","author":"Jones","year":"2007","journal-title":"J. Rehabil. Res. Dev."},{"key":"10.1016\/j.cct.2016.08.010_bb0115","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"author":"Food","key":"10.1016\/j.cct.2016.08.010_bb0120"},{"issue":"Suppl 2","key":"10.1016\/j.cct.2016.08.010_bb0125","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1111\/j.1524-4733.2007.00275.x","article-title":"Patient-reported outcomes to support medical product labeling claims: FDA perspective","volume":"10","author":"Patrick","year":"2007","journal-title":"Value Health"},{"key":"10.1016\/j.cct.2016.08.010_bb0130","series-title":"19th Annual Meeting of the International Society for Pharmacoeconomics and Patient Outcomes Research (ISPOR)","first-page":"5","article-title":"Acute bacterial skin and skin structure infections (ABSSSI): development of a new patient reported outcome (PRO)","author":"Powers","year":"2014"},{"key":"10.1016\/j.cct.2016.08.010_bb0135","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1128\/AAC.49.11.4658-4666.2005","article-title":"Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam","volume":"49","author":"Breedt","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cct.2016.08.010_bb0140","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1128\/AAC.49.6.2260-2266.2005","article-title":"Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections","volume":"49","author":"Weigelt","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cct.2016.08.010_bb0145","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1128\/AAC.00377-07","article-title":"Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection","volume":"51","author":"Rajendran","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cct.2016.08.010_bb0150","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.annemergmed.2009.03.014","article-title":"Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient","volume":"55","author":"Duong","year":"2010","journal-title":"Ann. Emerg. Med."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714416302087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714416302087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,9]],"date-time":"2018-09-09T06:29:59Z","timestamp":1536474599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714416302087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":28,"alternative-id":["S1551714416302087"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2016.08.010","relation":{},"ISSN":["1551-7144"],"issn-type":[{"type":"print","value":"1551-7144"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinician-reported lesion measurements in skin infection trials: Definitions, reliability, and association with patient-reported pain","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2016.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}